Associate Professor of Pathology, Harvard Medical School/Brigham and Women's Hospital/Dana-Farber Cancer Institute/Boston Children's Hospital
Pathology
Dr. Keith L. Ligon, MD
|
|
Give Review
Keith Ligon works in the field of Pathology. He attended University of Texas Medical School. Keith Ligon is also a published doctor. He has 91 publication published. The most recent publication is: Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
- Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- Integrated genomic characterization of a pineal parenchymal tumor of intermediate differentiation.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
- Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
- Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
- Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
- Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.
- Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study.
- D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
- Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
- Pediatric low-grade gliomas: How modern biology reshapes the clinical field.
- ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Pten loss in olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.
- Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy.
- Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
- Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK.
- Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
- DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape.
- Enhancing radiation therapy for patients with glioblastoma.
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- PDGFRA Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma.
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
- Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors.
- Somatic Mutations of PIK3R1 Promote Gliomagenesis.
- Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.
- Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.
- BRAF Duplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper.
- Prospective, high-throughput molecular profiling of human gliomas.
- Current clinical development of PI3K pathway inhibitors in glioblastoma.
- DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues.
- Emerging insights into the molecular and cellular basis of glioblastoma.
- Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations.
- Classifying human brain tumors by lipid imaging with mass spectrometry.
- Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas.
- Telomerase and Retrotransposons: Reverse Transcriptases That Shaped Genomes Special Feature Sackler Colloquium: Maintenance of tumor initiating cells of defined geneti...
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
- Human glioma growth is controlled by microRNA-10b.
- Glioma models: new GEMMs add "class" with genomic and expression correlations.
- The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.
- BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications.
- Development of Stereotactic Mass Spectrometry for Brain Tumor Surgery.
- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
- Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis.
- Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
- Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination.
- Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
- Profiling critical cancer gene mutations in clinical tumor samples.
- CRX is a diagnostic marker of retinal and pineal lineage tumors.
- Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
- Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.
- Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies.
- Malignant astrocytic glioma: genetics, biology, and paths to treatment.
- Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
- Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors.
- Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
- Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice.
- Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.
- Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution.
- Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.
- Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.
- Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
- A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway.
- Olig gene function in CNS development and disease.
- Development of NG2 neural progenitor cells requires Olig gene function.
- Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube.
- Histology-based expression profiling yields novel prognostic markers in human glioblastoma.
- Diffusion-weighted imaging of fungal cerebral infection.
- Molecular diversity of astrocytes with implications for neurological disorders.
- The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
- Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema.
- Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.
- Intermediate DNA methylation is a conserved signature of genome regulation.
- Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas.
- Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
- Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity.
Schools
University of Texas At Houston Medical School At Houston
Brigham and Womens Hospital
Boston Children39s Hospital
Doctors Specialties
- Neuropathology
- Pathology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
University of Texas Medical School
Hospital
-
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053363424 |
| Last Name Of The Provider | LIGON |
| First Name Of The Provider | KEITH |
| View All |
Similar Doctors
|
|
Dr. Robert P. Hasserjian, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Meredith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tejus A. Bale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Schell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Umberto De Girolami, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Isaac E. Stillman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen P. Naber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mariana A. Stoleru, MD
This Doctor is OpenDoctor Recommended.
|